{
  "id": "fda_guidance_chunk_0306",
  "title": "Introduction - Part 306",
  "text": "INTERIM OR ANNUAL REPORTS TO IRB/IEC AND AUTHORITY(IES) Interim or annual reports provided to IRB/IEC in accordance with 4.10 and to authority(ies) in accordance with 5.17.3 X X (where required) 8.3.20 SUBJECT SCREENING LOG To document identification of subjects who entered pre-trial screening X X (where required) 8.3.21 SUBJECT IDENTIFICATION CODE LIST To document that investigator/institution keeps a confidential list of names of all subjects allocated to trial numbers on enrolling in the trial. Allows investigator/institution to reveal identity of any subject X 8.3.22 SUBJECT ENROLMENT LOG To document chronological enrolment of subjects by trial X Contains Nonbinding Recommendations number 8.3.23 INVESTIGATION PRODUCTS ACCOUNTABILITY AT THE SITE To document that investigational product(s) have been used according to the protocol X X 8.3.24 SIGNATURE SHEET To document signatures and initials of all persons authorized to make entries and/or corrections on CRFs X X 8.3.25 RECORD OF RETAINED BODY FLUIDS/TISSUE SAMPLES (IF ANY) To document location and identification of retained samples if assays need to be repeated X X Contains Nonbinding Recommendations 8.4 After Completion or Termination of the Trial After completion or termination of the trial, all of the documents identified in Sections 8.2 and 8.3 should be in the file together with the following Title of Document Purpose Located in Files of Investigator/Institution Sponsor 8.4.1 INVESTIGATIONAL PRODUCT(S) ACCOUNTABILITY AT SITE To document that the investigational product(s) have been used according to the protocol. To document the final accounting of investigational product(s) received at the site, dispensed to subjects, returned by the subjects, and returned to sponsor X X 8.4.2 DOCUMENTATION OF INVESTIGATIONAL PRODUCT DESTRUCTION To document destruction of unused investigational products by sponsor or at site X (if destroyed at site) X 8.4.3 COMPLETED SUBJECT IDENTIFICATION CODE LIST To permit identification of all subjects enrolled in the trial in case follow-up is required. List should be kept in a confidential manner and for agreed upon time X 8.4.4 AUDIT CERTIFICATE (if available) To document that audit was performed X 8.4.5 FINAL TRIAL CLOSE-OUT MONITORING REPORT To document that all activities required for trial close-out are completed, and copies of essential documents are held in the appropriate files X Contains Nonbinding Recommendations 8.4.6 TREATMENT ALLOCATION AND DECODING DOCUMENTATION Returned to sponsor to document any decoding that may have occurred X 8.4.7 FINAL REPORT BY INVESTIGATOR",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 409920,
  "end_pos": 411456,
  "tokens": 512,
  "tags": [
    "clinical_trial",
    "consent",
    "data"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "mandatory",
  "created_at": "2025-10-23T02:25:44.699Z"
}